Pain Management News

Caregivers for those with Lennox Gastaut and Dravet syndrome reported that cannabidiol treatment led to improved nonseizure outcomes and reduced seizure burden, according to a study from Epilepsy Research.

The FDA has approved AvertD, the first DNA test to identify an elevated risk for developing opioid use disorder, according to a press release.

The FDA has issued a warning against the purchase or use of products that contain tianeptine, which has been illegally sold with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.

Long-term treatment with psychedelics holds the potential to transform the health care industry through millions in savings, according to an expert at a congressional briefing hosted by Johns Hopkins University.

Researchers identified multiple predictors of opioid overdose after an opioid prescription for chronic pain in a new study published in CMAJ.

An umbrella review published in The BMJ provided a breakdown of the associations between cannabis and health outcomes, highlighting the uncertain potential for clinical use.

Peer victimization and suicidality were associated with higher headache frequency in adolescents, while the association between headache and gender diversity weakened after controlling for other factors, according to research in Neurology.

New opioid use significantly increases the risk of death in older adults with dementia, according to research reported at the Alzheimer’s Association International Conference.

Patients seeking musculoskeletal care required substantial improvements in physical function and pain interference to significantly improve anxiety symptoms, according to results published in JAMA Network Open.

About 58% of pharmacies reported availability of buprenorphine for opioid use disorder at the time of patients’ requests, according to researchers.